Yes they work.  They also …. oooops, prove that you can improve your eyesight.   It’s literally in their own peer reviewed clinical research.

Background:  Myopia is measured in diopters. What it physically is, is length. A myopic eye is a longer eye, so a shorter eye is less myopia. That is not a theory, it is the definition of the measurement.

Which makes the whole argument run on one question. Can a myopic eye get shorter? You are told no, permanently and everywhere. The answer in peer-reviewed ophthalmology journals is yes, it has been measured repeatedly, including in adults, using the same instruments the clinics use. Those measurements are further down this page.

Myopia control lenses are the softer half of the same admission. MiSight, MiYOSMART and Stellest all work by steering eye growth with defocus, and all three are measured on axial length. The category exists because eyes respond to optical input. Nobody in the industry disputes that part. They sell it.

What myopia control lenses actually are

Three products dominate the category:

• MiSight (CooperVision). A daily contact lens for children age 8 to 12. FDA approved in November 2019, the first contact lens approved specifically to slow myopia progression. The 3-year trial of 135 children reported up to 59% less progression than standard lenses.
• MiYOSMART (HOYA). A spectacle lens using DIMS technology, launched 2018. The 2-year trial reported roughly 60% slower progression and 66% less axial elongation than single-vision lenses, with follow-up data at 3 and 6 years showing no rebound.
• Stellest (EssilorLuxottica). A spectacle lens using HALT technology, from 2020. The 2-year trial reported up to 67% reduction in progression, with every full-time wearer progressing less than 0.50 diopters per year.

Different brands, one identical idea: keep central vision sharp while placing myopic defocus on the peripheral retina, so the eye stops elongating toward blur.

The mechanism they all agree on

The science underneath these products comes largely from Earl Smith’s primate research: place hyperopic defocus on the peripheral retina and the eye elongates, becoming more myopic. Place myopic defocus there and elongation slows. The eye is not passively “getting worse.” It is tracking its optical environment, in both directions, and the peripheral retina is doing much of the steering.

This is not a fringe claim. It is the working assumption of a multi-billion-dollar product category, published in the journals, cleared by the FDA, and sold at a premium in the same shops that sell ordinary lenses.

And then you got to the retail optometrist …

Walk into a lens shop with an 8-year-old, and you may be offered a lens designed to steer the child’s eye growth with defocus, backed by trial percentages and a premium price.

But only if you pay them $500+ for this truth.  Otherwise you get the regular lenses, which actively make your eyes worse, by the same mechanisms that they describe they prevent with the expensive stuff. 

So can adult eyes improve?

Here is the honest version, without overclaim.

The myopia control trials were run on children because that is where myopia progresses fastest and where the premium product sells, and the lenses are marketed only for slowing progression. Nobody has run those trials on adult reversal. Axial shortening itself has now been measured in adults, which is covered in detail below, but how far it goes in an adult who changes only lenses and habits is untested. Anyone who tells you the kids’ trial percentages transfer to adults is ahead of the evidence.

What is well supported is the underlying rule: eyes respond to their optical environment throughout life. Ciliary muscle strain relaxes. Blur interpretation improves. And thousands of people who applied defocus principles deliberately, with reduced correction for close-up work and real distance-vision habits, have measured their own numbers stepping down over months and years. The realistic pace people report is slow, on the order of a diopter a year, not the dramatic percentages from the pediatric trials. Those are different claims and should stay different.

The point of the myopia control category is not that it proves reversal. It is that it demolishes the story where your eyes are a broken camera that only degrades. The industry’s own products say otherwise.

Axial shortening is in their own literature

Axial shortening happens. It is measured, it is published, and it happens in adults. Since a shorter eye is less myopia, that single fact settles the version of the argument you are usually handed, which is that a myopic eye can only ever get longer.

Here is the evidence, weakest to strongest.

Start with the animals, because the direction was established there first. Chicks, tree shrews, marmosets and rhesus macaques all showed axial shortening when given myopic defocus or allowed to recover from induced myopia. Recovery is not a controversial word in that literature.

Then the children:

• Orthokeratology. A database analysis of 10,093 children found a median axial shortening of 0.19 mm, individual reductions from 0.10 to 0.73 mm, and in some cases the shortening was maintained from one year up to seven years. A separate cohort of 37 children averaged 0.18 mm of shortening at twelve months.
• Repeated low-level red light. In a randomized trial, axial shortening greater than 0.05 mm occurred in 21.85% of treated children against 1.38% of controls at twelve months. In high myopia specifically, a multicentre randomized controlled trial reported shortening beyond 0.05 mm in 59% of the treated group and 0% of controls.
• Both combined. In 100 children aged 7 to 15, measured on an IOLMaster 500, the treated group shortened by 0.10 mm over twelve months while the control group elongated by 0.30 mm.

And then the part that matters most here, because the standard reply to everything above is that children’s eyes are still growing. Ninety-eight myopic adults, aged 23 to 31, four weeks of repeated low-level red light, axial length measured on a Lenstar LS-900. Mean axial length went from 24.63 mm to 24.57 mm, and 69% of them shortened by more than 0.05 mm. Adult eyes, optical biometry, peer reviewed, measurably shorter.

How much myopia is that? The conversion between millimetres and diopters is not a fixed constant, but the published range runs from about 1.44 to 3.00 diopters per millimetre. On that range the 0.19 mm median from the orthokeratology database is somewhere between a quarter and half a diopter of myopia, gone. Modest, real, and in the direction you are told is impossible.

They had no idea (convenient) till they had a patented product.  

There are now registered clinical trials with titles like “Repeated Low-Level Red-Light Therapy Shortens Axial Length” and “Repeated Low-Level Red-Light Therapy for Shortening Axial Length.” The disputed claim is the title of the trial.

The device behind most of that work holds joint patents granted in the United States, Australia and Europe, with regulatory approval across the UK, Japan, Australia and elsewhere, CE marking in Europe and TGA approval in Australia. The industry’s own trade publication describes the therapy as the only intervention that has demonstrated consistent axial length shortening, as opposed to merely slowing elongation.

So the same field that treats axial shortening as impossible when an unlicensed person raises it will print it in a journal, register it as a trial endpoint and put it on a product page, once there is something to sell. None of that requires a conspiracy. It requires only the ordinary way medicine adopts an idea. It becomes sayable when it becomes billable.

What we have measured, going back a decade

The industry evidence above says the direction is possible. It does not say anything about this method, because nobody has run a trial of reduced correction and habit change in adults. What exists on our side is a decade of documented cases, published as they happened.

The case registry indexes 273 adult cases drawn from publicly published first-hand reports between 2013 and 2026. Median starting myopia is -5.25 D, with a range from -0.75 to -13.75 D, and the median recorded reduction is -2.00 D. Forty-two of those cases carry external corroboration, meaning an optometrist measurement, a driving licence vision test or similar. The dataset and the case series paper are both deposited with DOIs, at 10.5281/zenodo.21230819 and 10.5281/zenodo.21016339.

Beyond the registry there are 87 optometrist-confirmed reports in the archive going back to 2015, including a case where the reduction was recorded with biometry, which is the same class of measurement the trials above rely on. Seventy-nine of the registry cases started above -6.00 D, so high myopia is the largest band in the data, not the edge case.

Put the two halves together and the position is straightforward. The categorical claim, that a myopic eye cannot get shorter, is no longer defensible, because the people who make that claim publish measurements of the opposite. What is still open is how far it goes in an adult who changes nothing but lenses and habits. That question deserves a study. It has not been given one.

What this means practically

If eyes track their optical input, then the input you give your eyes all day is not neutral. Full-strength distance correction worn at 50 cm from a screen creates exactly the hyperopic defocus that the research links to elongation. That is the everyday version of the signal Earl Smith imposed on purpose in the lab.

The practical response is not a product. It is knowing your own numbers, watching them over time, and managing the optical signal you live in: appropriate correction for the distance you are actually using, and regular time where your eyes work at real distances. That is measurable. Your centimeter measurement and your diopter numbers move slowly, but they move, and you can track them yourself.

Related reading: The Defocus Method: The Biology Endmyopia Acts On.

Common questions

Do myopia control lenses work for adults?

They are neither approved nor marketed for adults, and the trials were run on children age 8 to 16. Adults are not in the fast progression phase those trials measured, so the “slow it down” framing mostly does not apply. What carries over to adults is the mechanism the lenses are built on: eyes respond to peripheral defocus. Adults apply that principle differently, through lens choices and visual habits rather than a pediatric product.

Do defocus lenses reverse myopia?

No. The trials show slowed progression in children, not reversal, and the manufacturers do not claim reversal. The relevance to reversal is indirect: the products prove that eye growth follows optical input, which contradicts the idea that myopia is a fixed, one-way condition.

Why are myopia control lenses only sold for children?

The official answer is that trials were run on children because that is when eyes grow fastest and progression is easiest to measure. The unofficial observation: adult customers who believe their eyes only get worse are repeat buyers of progressively stronger lenses, and there is no premium product to sell an adult who learns their eyes still respond to optical input.

Are these lenses worth the price for a child?

That is between parents and their eye care provider, and the trial data is real. Worth knowing: the same defocus principle the lenses automate, less close-up strain and more real distance time, is available to any family for free, and the trials on outdoor time in children show meaningful effects on progression as well.

What is peripheral defocus in simple terms?

Where the focus of light lands relative to the peripheral retina. If light focuses behind the peripheral retina (hyperopic defocus), the eye tends to elongate, chasing the focal point. If it lands in front (myopic defocus), elongation slows. Myopia control lenses keep your central vision sharp while deliberately creating that second kind of defocus.

Has axial length shortening ever been measured in adults?

Yes. A study of 98 myopic adults aged 23 to 31 recorded mean axial length falling from 24.63 mm to 24.57 mm over four weeks of repeated low-level red light therapy, measured on a Lenstar LS-900, with 69% of participants shortening by more than 0.05 mm. That is not a trial of this method, and both the durability and the mechanism are still debated. What it settles is narrower and still important: an adult myopic eye can measurably shorten.